Lucjan Wyrwicz: Grab the most recent issue of the Lancet Oncology with the full report of the Keynote-859 study

Lucjan Wyrwicz, Professor at the National Institute of Oncology Maria Skłodowska-Curie – National Research Institute, recently posted on LinkedIn:

“Saturday morning coffee with a good lecture? Why not! Grab the most recent issue of the Lancet Oncology with the full report of the Keynote-859 study (the link is pasted below).

This study addressed the value of adding pembrolizumab to the standard chemotherapy in the treatment of advanced gastric cancer. The positive outcomes are more pronounced in „the inflamed” tumors (PD-L1 positive tumors covering 3/4 of pts). But also the general population outcomes are improved (screenshot below).

Congratulations to Dr. Rha and the study team. Please notice that this treatment has just been supported by the announced ESMO23 Living ESMO Guidelines.

Thank you Lancet Oncology as the senior author of this paper I must admit collaboration with such a prominent publisher as Lancet was both pleasant and fruitful!”

For the article click here.
Source: Lucjan Wyrwicz/LinkedIn